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Introduction
Osteosarcoma is the most frequent malignant pri-
mary bone tumor that develops mainly in the young,
the median age of diagnosis being 18 years [1]. Despite
recent improvements in chemotherapy and surgery, the
problem of non-response to chemotherapy remains.
Thus, current strategies for the treatment of high-grade
osteosarcoma fail to improve its prognosis [2, 3], main-
ly because of chemotherapy resistance.This poor prog-
nosis of osteosarcoma warrants new therapeutic strate-
gies to improve the overall rate of survival.
Bisphosphonates (BPs) are stable synthetic ana-
logues deriving from endogenous pyrophosphate
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Abstract
We recently demonstrated original anti-tumor effects of zoledronic acid (Zol) on osteosarcoma cell lines inde-
pendently of their p53 and Rb status. The present study investigated the potential Zol-resistance acquired by
osteosarcoma cells after prolonged treatment. After 12 weeks of culture in the presence of 1 µm  Zol, the
effects of high doses of Zol (10–100 µm) were compared between the untreated rat (OSRGA, ROS) and
human (MG63, SAOS2) osteosarcoma cells and Zol-pretreated cells in terms of cell proliferation, cell cycle
analysis, migration assay and cytoskeleton organization. Long-term treatment with 1 µm Zol reduced the sen-
sitivity of osteosarcoma cells to high concentrations of Zol. Furthermore, the Zol-resistant cells were sensitive
to conventional anti-cancer agents demonstrating that this resistance process is independent of the multidrug
resistance phenotype. However, as similar experiments performed in the presence of clodronate and
pamidronate evidenced that this drug resistance was restricted to the nitrogen-containing bisphosphonates,
we then hypothesized that this resistance could be associated with a differential expression of farnesyl diphos-
phate synthase (FPPS) also observed in human osteosarcoma samples. The transfection of Zol-resistant cells
with FPPS siRNA strongly increased their sensitivity to Zol.This study demonstrates for the first time the induc-
tion of metabolic resistance after prolonged Zol treatment of osteosarcoma cells confirming the therapeutic
potential of Zol for the treatment of bone malignant pathologies, but points out the importance of the treatment
regimen may be important in terms of duration and dose to avoid the development of drug metabolic resistance.
Key words: osteosarcoma • bisphosphonate • zoledronic acid • metabolic resistance •
farnesyl diphosphate synthase
J. Cell. Mol. Med. Vol 12, No 3, 2008 pp. 928-941
*Correspondence to: DOMINIQUE HEYMANN, 
Laboratoire de Physiopathologie de la Résorption
Osseuse et Thérapie des Tumeurs Osseuses Primitives,
EA3822 - INSERM ERI 7, Faculté de Médecine, 1 rue
Gaston Veil, 44035 Nantes cedex 1, France.
Tel.: 33 240 412 845
Fax: 33 240 412 860
E-mail: dominique.heymann@univ-nantes.fr
© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
doi:10.1111/j.1582-4934.2007.00141.x
J. Cell. Mol. Med. Vol 12, No 3, 2008
929© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
(PPi) [4]. Various side chains can be added to the
central carbon atom, thus producing a range of BPs
with differential clinical activity and potency [5]. The
most common therapeutic application of BPs is
osteoporosis, and their use has been extended to the
treatment of malignant osteolysis and hypercal-
cemia. Two groups of BPs can be identified including
non-nitrogen-containing and nitrogen-containing
BPs. The BPs that lack a nitrogen atom, closely relat-
ed to PPi (such as clodronate, etidronate and tilu-
dronate) are metabolized intracellularly to cytotoxic
analogues of ATP and decrease osteoclast survival
[5]. In contrast, nitrogen-containing BPs (such as
pamidronate, alendronate, risedronate, ibandronate
and zoledronate) induce apoptosis of osteoclasts by
inhibiting enzymes of the mevalonate pathway, espe-
cially farnesyl diphosphate synthase (FPPS) [6, 7].
FPPS prevents the biosynthesis of cholesterol and
isoprenoid lipids (FPP and geranylgeraniol diphos-
phate) which are required for the prenylation of small
GTPases (i.e. Ras, Rho and Rac), a biochemical
reaction essential for the anchorage of small
GTPases to cell membranes and to protein-protein
interactions [8]. In addition to their powerful anti-bone
resorption effects, recent in vitro studies evidenced a
direct anti-tumor activity exerted by zoledronic acid
(Zol) on several cancer cells (myeloma, carcinoma
and sarcoma) [9, 10]. Preclinical data confirmed the
Zol anti-tumor activity in experimental models of
bone tumors. Among these studies, we reported
recently the enhancement of tumor regression and
tissue repair when Zol is combined with ifosfamide in
rat osteosarcoma [11] and that Zol suppresses lung
metastases and prolongs overall survival of
osteosarcoma-bearing mice [12]. Furthermore,
recent clinical trials in patients suffering from malig-
nant bone diseases demonstrated that Zol was safe
and well tolerated at the approved dose of 4 mg i.v.
every 3–4 weeks [4]. Because the main difficulty
encountered in treating cancer relates to mutations
carried by many tumor cells in key genes such as
p53, Rb or proteins affecting caspase signalling, we
demonstrated selective and original anti-tumor
effects of Zol on several osteosarcoma cell lines
independently of their p53 and Rb status [13].
Indeed, Zol inhibited osteosarcoma cell proliferation
through a cell cycle arrest in S and G2/M phases and
induced atypical apoptosis independent of caspase
activation, characterized by the translocation of
Apoptosis Inducing Factor and Endonuclease-G [13].
These data now allow to consider these molecules
as potential therapeutic agents in clinical trials of
tumor bone pathologies independently of the p53
and Rb status of the tumor.
The optimization and increase in specificity of can-
cer treatments has improved their efficacy and
reduced the associated adverse effects, but unfortu-
nately has not yet resulted in a cure for the majority
of patients. Studies of the mechanisms by which
tumor cells escape treatment is essential to circum-
vent drug resistance in cancer cells and to design
new therapeutic protocols that are not subject to
these drug-resistances [14]. Two types of resistance
mechanism have been identified [15]. The first one
results in resistance restricted to a specific drug or
limited to a small number of related drugs, which can
be bypassed by modification of the chemotherapeu-
tic agent. The second mechanism confering multi-
resistance to many unrelated drugs, is called mul-
tidrug resistance (MDR) and is responsible for many
failures of cancer treatment [16]. The most common
mechanisms responsible for the various forms of
resistance are the overexpression of efflux pumps,
inhibition of apoptosis, increased repair of DNA dam-
age, mutations in key cell cycle checkpoint genes
and increased or altered drug targets [14]. Similar to
non-osseous malignancies, osteosarcomas fre-
quently exhibit a MDR phenotype explaining why
patient survival has not improved since the mid-
1980s despite advances in anticancer therapies.
Because Zol represents a potential novel anti-neo-
plastic agent for the therapy of osteosarcoma, the
present study investigated the potential development
of innate and/or acquired resistance to Zol and the
molecular mechanisms involved in this phenomenon.
Material and methods
Patients
This study included seven patients (three females aged
41–93 years, four males aged 16–79 years) that were
referred to our institution for the treatment of osteosarcoma.
All cases were diagnosed as osteogenic osteosarcoma
based on histological samples obtained by open biopsies.
The experimental procedures followed in the present study
were in accordance with the ethical standards of the respon-
sible institutional committee on human experimentation and
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with Helsinki Declaration of 1975, revised in 1983.The study
was approved by the institutional ethic committee.
Cells, culture conditions and 
establishment of Zol-resistant cell lines
The rat osteosarcoma OSRGA cell line was initially estab-
lished from a radio-induced osteosarcoma [17, 18]. The rat
ROS17/2.8 cell line was kindly provided by Prof. H.J.
Donahue (Penn State University, USA), and the human
MG63 and SAOS2 cell lines were purchased from ATCC
(USA). These cell lines were cultured in DMEM
(BioWhittaker, Belgium) supplemented with 5% Fetal Calf
Serum (Hyclone, France) and 2 mM L-glutamine
(BioWhittaker). Rat and human osteosarcoma cell lines
resistant to Zol (MG53res, SAOS2res, ROSres,
OSRGAres) were established by 3 months of continuous
treatment with 1 µm Zol.
Cell growth and viability
Cell growth and viability were determined by a cell prolifer-
ation reagent assay kit using sodium 3'[1-(phenylaminocar-
bonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro)benzene sul-
fonic acid hydrate (XTT) (Roche Molecular Biomedicals,
Germany). Two thousand cells/well were plated into 96-well
plates and cultured for 72 hrs in culture medium in the
presence or the absence of 10–12–10–4 M Zol. Zol was pro-
vided by Novartis Pharma AG (Basel, Switzerland) as the
disodium hydrate form. In another set of experiments, cells
were treated for 72 hrs in the presence or the absence of
10–9–10–6 M methotrexate (Sigma, France), doxorubicine
(Sigma) and 1–50 µg/ml mafosfamide (Baxter, France),
10–1000 µm clodronate (Sigma), 1–500 µm pamidronate
(Sigma) and 5 µm verapamil (Sigma). After the culture peri-
od, XTT reagent was added to each well and incubated for
5 hrs at 37°C, the corresponding absorbance was then
determined at 490 nm. Cell viability was also assessed by
trypan blue exclusion and live and dead cells were scored
manually. Cell death was also monitored microscopically
after Hoechst n°33258 staining (Sigma). In this experiment,
cells were seeded at 104 cells/well in a 24-well plate and
treated or not with 10 m Zol for 48 hrs or 100 nm stau-
rosporine (Sigma) for 16 hrs, stained by 10 g/ml Hoechst
reagent for 30 min at 37°C and then observed under UV
microscopy (DMRXA, Leica, Germany). Statistical evalua-
tion of the data was performed using the ANOVA test.
Western blot analysis
Zol-treated cells were lysed in RIPA buffer (150 mM NaCl,
5% Tris pH 7.4, 1% NP-40, 0.25% Na deoxycholate, 1 mM
Na3VO4, 0.5 mM PMSF, 10 µg/ml leupeptin, 10 µg/ml apro-
tinin). Protein concentration was determined by the BCA kit
(Pierce Chemical, USA). A total of 50 µg of total cell lysate
protein were run on SDS-PAGE, electrophoretically trans-
ferred to Immobilon-P membrane (Millipore, MA, USA).The
membrane was blotted with antibodies anti-p-Rb (Ser
807/811), -p-cdc2 (tyr15), -actin (Cell Signaling
Technologies, USA), -p21WAF1(BD Biosciences, USA) and
the unprenylated form of Rap1A (Santa Cruz, USA) to indi-
rectly quantified FPPS enzymatic activity, in PBS, 0.05%
Tween 20 and 3% bovine serum albumin (BSA). The mem-
brane was washed and probed with the secondary anti-
body coupled to horseradish peroxidase. Antibody binding
was then visualized with the enhanced chemolumines-
cence system (ECL Kit; Roche Molecular Biomedicals).
The band densities were measured using the GeneTools
computer software program (SynGene).
Caspase -1, -3 and -8 activities
Caspase -1, -3 and -8 activities were assessed on 10 µl of
total Zol-treated or not cell lysates using the kit
CaspACETM Assay System, 'Fluorometric' (Promega,
USA) following the manufacturer's recommendations. Cells
treated with UV light for 30 sec 24 hrs before harvesting
were used as a positive control. Results were expressed in
arbitrary units referred to the total protein content.
Cell cycle analysis
OSRGA, MG63 and SAOS2 cells were incubated in the
absence or the presence of 10 µm Zol for 48 hrs,
trypsinized, washed twice and incubated in PBS containing
0.12% Triton X-100, 0.12 mM EDTA and 100 g/ml ribonu-
clease A. Then 50 g/ml propidium iodide were added to
each sample for 20 min at 4°C. Cell cycle distribution was
analyzed by flow cytometry (FAC Scan), based on 2N and
4N DNA content.
Time-lapse microscopy and 
confocal microscopic analysis
For time-lapse experiments, cells were seeded at 5  104
cells/well and cultured in 6-multiwell plates in the absence
or the presence of 10 µm Zol. Phase-contrast photographs
(Leica) were taken every 10 min during 60 hrs and edited
using the MetamorphTM software. Cell divisions and apop-
totic cells were then manually scored. To study cell migra-
tion, cells plated in 6-well plates and cultured until conflu-
ence were treated or not with 10 µm Zol for 24 hrs before
a slit was made in the cell monolayer. Actin filament detection
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was performed after cell treatment with or without 
10 µm Zol fixed in 4% paraformaldehyde and stained with
FITC-conjugated phalloidin (0.25 µg/ml; Sigma). Cover
glasses were fitted with the Long Pro Kit (Molecular
probes). Images were collected on a Leica TCS-SP1 con-
focal microscope with 63/1.4x oil immersion lens. The digi-
tal images were visualized with a 24-bit imaging system
including Leica's TCS-NT software and projections were
generated from z-stacks.
siRNA gene silencer
The FPPS gene expression was knocked down using spe-
cific human and rat FPPS siRNA (Ambion, France) and the
INTERFERinTM transfection reagent (Polyplus transfection,
France). Cells were seeded at 40% confluency in a 24-well
plate 1 day before transfection. In each well 10 nm siRNA
duplexes diluted in serum-free medium were incubated
with 2 µl of INTERFERinTM for 30 min at room temperature.
Then, 100 µl mixture per well were added onto the cells
and incubated at 37°C. The 72 hrs-Zol treatment started 
24 hrs after siRNA transfection. For each condition 
tested, a negative siRNA control was used (Santa Cruz
biotechnology, Germany). Additional experiments were
performed in the presence of geranylgeraniol (GGO)
(Sigma, France).
RT-PCR analysis 
Total RNA was isolated from cultured OSRGA, MG63 and
SAOS2 cells using the TRIzol reagent (Invitrogen, France).
First, RNA was reversed-transcribed (RT), using 400 U
MMLV-RT from Invitrogen, then 2 µl of the RT reaction mix-
ture were subjected to PCR using upstream and down-
stream primers to determine the expression of rat and
human FPPS [Human FPPS sense: AGATCT-
GTGGGGGTCTTCCT, anti sense: TCCCGGAATGCTAC-
TACCAC; Rat FPPS sense: AGTACAATCGGGGTCT-
GACG, anti sense: CGCGATAGGCAGGTAGAAAG] and
0.25 µl of 5 U/µl Taq polymerase (Eurobio, France). After
the number of PCR cycles was increased, a plot was done
for each sample, the cycle values corresponding to the lin-
ear part of the amplification curve were then determined
(28 cycles, Tm = 58°C) and used to quantify the message
versus the 18S signal determined in the same way. The
PCR products were electrophoresed in 1% agarose gel-
containing ethidium bromide. The band densities were
measured using the GeneTools computer software pro-
gram. Three independent experiments were performed for
each gene and a representative experiment is shown in the
Results section.
Results
Osteosarcoma cell lines develop Zol-
resistance after long-term continuous
treatment with low-dose Zol
Consistent with previous results [11, 12, 19], Zol
treatment of Zol-sensitive rat ROS, OSRGA (Fig. 1A)
and human MG63, SAOS2 (Fig. 1B) osteosarcoma
cells strongly reduced their proliferation and induced
the cell death without any caspase 1, 3 or 8 activa-
tion (data not shown). Thus, 0.1–100 µM Zol
decreased the viable cell number in a dose-depend-
ent manner (IC50: 1–8 µM) as revealed by the XTT
assay. After 3 month continuous treatment with 1 µm
Zol, rat and human osteosarcoma cells became less
sensitive to Zol and resistant cell lines (OSRGAres,
ROSres, MG63res, SAOS2res) were then progres-
sively established (Fig. 1A). Indeed, the potency of
Zol to affect cell proliferation was strongly reduced on
human resistant cell lines and Zol was ineffective on
rat resistant cell lines (Fig. 1A).
The influence of this resistance process was also
assessed on the other known activities of Zol on
tumor cells [cell cycle (Fig. 1B), DNA checkpoints
(Fig. 1B), cytoskeleton (Fig. 1C), cell migration (Fig.
1C) [13]). Cell cycle analysis was performed after 48
hrs of 10 µm Zol-treatment.The results obtained con-
firmed that 48 hrs of Zol-treatment induced a strong
cell cycle arrest in S and G2/M phases in Zol-sensi-
tive OSRGA cells (Fig. 1B, [13]) and showed that Zol-
treatment did not modulate the cell cycle in
OSRGAres cells (Fig. 1B). Indeed, the number of
cells in S, G2/M phases strongly increased from 35%
to 53% for OSRGA cells in the presence of 10 µm Zol
concomitantly with a decrease of cells in G0/G1
phase: 42% versus 64% (Fig. 1B). A similar phenom-
enon was observed in human osteosarcoma cell
lines (data not shown). We therefore investigated by
western blot whether the DNA checkpoint proteins
were involved in the cell cycle blockade observed in
the presence of Zol. Thus, the treatment of sensitive
OSRGA cells by 10 µm Zol increased the inactive
form of cdc2 (p-cdc2, Tyr15) after 72 hrs of treatment.
Simultaneously, Zol strongly reduced p21 expression
and transiently upregulated Rb phosphorylation (Ser
807 and 811) after 24 hrs of Zol treatment (Fig. 1B).
No modulation of p-cdc2, Rb and p21 was observed
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in OSRGAres cells regardless of the duration of Zol
treatment (Fig. 1B).
As Zol has been shown to disturb cytoskeletal organ-
ization and to inhibit cell migration [13], we wondered
whether Zol could alter such parameters in OSRGAres
cells. Confocal microscopy revealed a major disorgani-
zation of the actin stress fibres associated with mem-
brane ruffling in sensitive OSRGA cells treated with 
Fig. 1 Osteosarcoma cell lines
develop Zol-resistance after long-
term of continuous treatment with
low doses of Zol. (A) rat (OSRGA,
ROS) and human (MG63, SAOS2)
sensitive and resistant (correspon-
ding cell Name-res) osteosarcoma
cell lines were treated with increas-
ing concentrations of Zol (0.1–
100 µm) for 72 hrs. The number of
viable cells was then measured
using the XTT assay. Graphs rep-
resent the mean values of three
independent experiments per-
formed in triplicate. *** P < 0.001.
Statistical evaluation of the data
was performed using the ANOVA
test. (B) Cell cycle distribution of
OSRGA and OSRGAres, treated
or not with 10 µm Zol for 48 hrs
was analyzed by propidium iodide
staining and FACS analysis. G1/S
and G2/M DNA checkpoints were
analyzed by western blot and com-
pared between sensitive and
resistant OSRGA osteosarcoma
cell lines in the presence or
absence of 10 µm Zol for 24, 48
and 72 hrs. All experiments were
repeated three times and a repre-
sentative blot is shown. (C) Zol
effects on organization of actin
stress fibres were observed by
confocal microscopy after phalloï-
dine staining. The actin network
reorganization was associated with
membrane ruffling (white arrow) in
Zol-sensitive OSRGA cell line
(Original magnification:1000). Zol
effects on cell migration were also
analyzed by time-lapse microscopy.
The horizontal bars represent the
limit of the slit cut performed on the
cell monolayer at the start of the
experiment (Original magnification:
100). (D) Farnesyl diphosphate
synthase (FPPS) transcription
level was determined by semi
quantitative RT-PCR in OSRGA
sensitive and resistant cell lines.
The 18S was used as a control.
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10 µm Zol for 72 hrs, this was never observed in
OSRGAres cells (Fig. 1C). Moreover, as shown by the
time-lapse assay, 10 µm Zol totally blocked the migra-
tion of sensitive OSRGA cells but was not able to abol-
ish migration of OSRGAres cells (Fig. 1C).
The molecular mechanism involved 
in the reduced-Zol sensitivity is not
associated with a multidrug 
resistance (MDR) phenotype and is
restricted to the nitrogen-containing
bisphosphonates
The potential role of the MDR phenotype in the Zol
resistance phenomenon was assessed by XTT
assays. The MDR phenotype is conventionally
defined as the resistance of cells to conventional
chemotherapeutic agents such as mafosfamide,
methotrexate and doxorubicin [20, 21]. The XTT
assays revealed that OSRGAres cells were still
always sensitive to increasing doses of mafosfamide,
methotrexate and doxorubicin (Fig. 2). Furthermore,
5 µm verapamil, a P-gp pump inhibitor [22] was not
able to abolish the Zol resistance (Fig. 2). Overall,
these data demonstrate that the Zol resistance was
not associated with MDR phenotype. In addition,
similar experiments performed in the presence of
clodronate, a non-nitrogen containing-BP [4],
revealed that OSRGAres are as sensitive to clo-
dronate as they are to lower concentrations of Zol
(Fig. 2). When, osteosarcoma cells were treated with
another nitrogen-containing BP, pamidronate that
also targets FPPS, it significantly reduced Zol-sensi-
tive OSRGA proliferation in contrast to OSRGAres
cells, which are also resistant to pamidronate 
(Fig. 2). Similar results have been obtained with the
osteosarcoma cell lines MG63 and SAOS2 (data not
shown). These experiments demonstrated that the
Zol-resistance phenomenon in osteosarcoma cells
appears to be MDR-independent and is apparently
restricted to nitrogen-containing BPs.
Farnesyl diphosphate synthase (FPPS)
is implicated in the Zol-resistance
mechanism of osteosarcoma cell lines
FPPS being the main molecular target of nitrogen
containing BPs [23], the FPPS transcript expression
was analyzed by RT-PCR and compared in sensitive
OSRGA and OSRGAres cells (Fig. 1D). Thus, the
Zol-resistant cells expressed a higher level of FPPS
mRNA than the sensitive cells. To further determine
the involvement of FPPS in the Zol-resistance mech-
anism of human and rat osteosarcoma cells, the
effect of Zol on OSRGA, OSRGAres, MG63 and
SAOS2 was analyzed after transfection with FPPS
siRNA. Semi-quantitative RT-PCR analysis was used
to evaluate the efficacy of FPPS siRNA on FPPS
mRNA expression. In all experiments, FPPS mRNA
levels were significantly decreased in FPPS siRNA-
transfected cell lines compared to the siRNA control
(Fig. 3A). Inhibition of FPPS activity was then
assessed indirectly by the expression of the unpreny-
lated form of the small GTPase Rap1A (unRAP1A)
that is expressed after inhibition of FPPS [24, 25]
(Fig. 3B). The transfection of Zol-sensitive cells with
FPPS siRNA strongly increased their sensitivity to
Zol in all osteosarcoma cell lines studied. Indeed,
FPPS siRNA transfection modified the unRAP1A
expression kinetic in OSRGA, MG63 and SAOS2
cells. In the presence of FPPS siRNA, unRAP1A
expression was strongly induced by 1 µm Zol treat-
ment for 24 hrs whereas its expression was only
observed with 10 µm Zol treatment for 48 hrs in con-
trol siRNA transfected cells (Fig. 3B). In OSRGAres
cells, a very weak expression of unRAP1A was
observed after Zol treatment. Interestingly, FPPS
siRNA re-induced the sensitivity to Zol treatment in
these resistant cells to a level comparable to parental
OSRGA cells transfected with FPPS siRNA. Thus,
the unRAP1A expression was observed after 24 hrs
treatment with 1 µm Zol in FPPS siRNA-OSRGAres
transfected (Fig. 3B). Similarly, micoscopic observa-
tions confirmed the FPPS siRNA effects on the sen-
sitization of osteosarcoma cells to Zol treatment 
(Fig. 3C). Thus, an increase of floating cell number
associated with an inhibition of cell proliferation was
observed after transfection of all osteosarcoma cell
lines with FPPS siRNA (Fig. 3C).
XTT analyses were performed to determine the
impact of FPPS siRNA on Zol activity (Fig. 3D).
Transfection with FPPS siRNA significantly
increased the sensitivity to Zol treatment of all
osteosarcoma cell lines analyzed (Fig. 3D). The sen-
sitivity to 10 µm Zol was up-modulated by 22%, 31%,
53% and 42% in OSRGA, OSRGAres MG63 and
SAOS2, respectively, in the presence of FPPS siRNA
compared to the control siRNA (Fig. 3D).
Furthermore, the efficacy of FPPS siRNA occured for
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lower doses of Zol in OSRGAres compared to
OSRGA cells (respectively 22% and 1% increase of
sensitivity in the presence of 0.1 µm Zol) (Fig. 3D).
siRNA FPPS increases the Zol-induced
blockade of the cell cycle in S, G2/M
phases in osteosarcoma cell lines
We previously demonstrated that Zol induces
osteosarcoma cell cycle arrest in S, G2/M phases in
OSRGA sensitive cells [13]. To determine whether
FPPS siRNA could modulate this sensitivity, the cell
cycle of FPPS siRNA-transfected osteosarcoma cells
was analyzed by flow cytometry. Figure 4 reveals that
FPPS siRNA accentuates the Zol-induced effects
observed on cell-cycle distribution, leading to a signif-
icant increase of cells blocked in S phase compared
to the control siRNA. Indeed, the number of cells in S
phase increased from 26% to 30% for OSRGA, from
20% to 26% for MG63, from 34% to 46% for SAOS2
and from 23% to 38% for OSRGAres cells in the pres-
ence of FPPS siRNA compared to the control siRNA
after 48 hrs of treatment with 10 µm Zol (Fig. 4).
Furthermore, these observations were concomitant
with a significant reduction of the cell number in
G0/G1 phase: 35% versus 42% for OSRGA, 61% ver-
sus 69% for MG63, 36% versus 57% for SAOS2 and
41% versus 53% for OSRGAres.
Geranyl geraniol (GGO) reversed the
FPPS siRNA effects in 
osteosarcoma cell lines
To determine whether the effects previously demon-
strated for the FPPS siRNA in osteosarcoma cells are
reversible, FPPS siRNA transfected cells treated with
Fig. 2 The molecular mechanism involved in the reduced-Zol sensitivity is not associated with a multidrug resistance
(MDR) phenotype and is restricted to the nitrogen-containing bisphosphonates. OSRGA and OSRGAres sensitivity to
conventional anti-cancer agents mafosfamide, methotrexate, doxorubicin and sensitivity to Zol in the presence or
absence of a P-gp pump inhibitor (5 µm verapamil) was analyzed by the XTT assay. Similar experiments were per-
formed in the presence of clodronate and pamidronate. Graphs represent the mean values of three independent exper-
iments performed in triplicate. Error bars represent the standard deviation. ***P < 0.001. Statistical evaluation of the
data was performed using the ANOVA test.
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increasing doses of Zol were cultured in the presence
of 25 µm geranylgeraniol, the FPPS metabolic product
(Fig. 5). GGO protected rat and human osteosarcoma
cell lines from the effects of Zol in the FPPS siRNA-
transfected cells and totally reversed FPPS siRNA
effects (Fig. 5A).We therefore investigated by western
blot the expression kinetic of unRAP1A in the pres-
ence of 25 µm GGO in FPPS siRNA-transfected cells
(Fig. 5B). GGO totally abolished unRAP1A expres-
sion similar to what had been observed in Zol-resist-
ant cell lines (Fig. 3B). Overall, these data then
strengthen our conclusion that FPPS is involved in
the Zol-resistance mechanism.
Dual origin of Zol resistance:
innate and/or acquired 
To explain the origin of the Zol-resistance observed
in osteosarcoma cell lines, two hypotheses can be
proposed: (i ) an innate resistance mechanism linked
to differential levels of FPPS expression and associ-
ated with selection of a sub-population of cells
expressing a higher FPPS activity, (ii ) an acquired
resistance mechanism linked to an increased FPPS
transcription level as a feedback response to long-
term, low-dose Zol treatment. To distinguish between
these two hypotheses, OSRGA osteosarcoma cell
Fig. 3 Involvement of farnesyl diphosphate synthase (FPPS) in the Zol-induced resistance mechanism in osteosarco-
ma. (A) Farnesyl diphosphate synthase (FPPS) transcription level was determined by semi quantitative RT-PCR in
FPPS siRNA transfected cell lines compared to the siRNA control cells. The 18S was used as a control. (B) Western
blot analysis of unprenylated RAP1A (unRAP1A) from OSRGA cell lines transfected with FPPS siRNA and control
siRNA, treated 24 and 48 hrs with 1 and 10 µm Zol. All experiments were repeated three times, and a representative
blot is shown. (C) Photomicrographs of FPPS siRNA transfected cells after 48 hrs with 10 µm Zol compared to control
siRNA. Original magnification: 100. (D) Rat (OSRGA, OSRGAres) and human (MG63, SAOS2) osteosarcoma cell
lines were transfected with FPPS siRNA and treated after 24 hrs of culture by increasing concentrations of Zol (0.1–10
µm) for 72 hrs. The number of viable cells was then determined using the XTT assay. Histograms represent the per-
centage of the increased sensitivity to Zol in the presence of FPPS siRNA compared to control siRNA.Values are mean
of three independent experiments performed in triplicate. Error bars represent the standard deviation.
935© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
936 © 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
lines were treated with low Zol concentrations (1–104
pM) for 72 hrs (Fig. 6A). Low concentrations of Zol
induced a 60% increase of viable cells and up-mod-
ulated the expression of FPPS mRNA in a dose-
dependent manner (Fig. 6A), these results support
acquired resistance to Zol. Since a potential mecha-
nism of innate resistance could be also envisaged,
OSRGA cell line was cloned by limiting dilution and
the expression of FPPS was analyzed by semi-quan-
titative RT-PCR (Fig. 6B). Several clones were isolat-
ed with heterogenous sensitivity to Zol treatment
(Fig. 6B). Furthermore, the isolated clones
expressed differential levels of FPPS related to their
sensitivity to Zol treatment, these results support
innate resistance to Zol (Fig. 6B). Similarly, we ana-
lyzed the transcriptional expression of FPPS in seven
human osteosarcoma samples analyzed by semi-
quantitative RT-PCR before any chemotherapy (Fig.6C).
The results revealed that a very high heterogeneity of
FPPS expression in these patients strengthening the
hypothesis of innate resistance to Zol.
Discussion
The first effects of BPs on calcium metabolism were
discovered over 30 years ago, and these drugs have
become the most widely used agents in the treat-
ment of bone diseases associated with excessive
resorption (osteoporosis, malignant osteolysis, etc).
The recent evidences of an anti-tumor effect of nitro-
gen-containing BPs have led to investigation of the
potential-acquired resistance mechanism. Indeed,
failure of anti-cancer therapies often occur from
innate or acquired drug resistance of the tumor cells
to the chemotherapeutic agents [26]. In this context,
the elucidation of potential resistance mechanisms to
the Zol will allow adaptation of the treatment regimen
in terms of duration and dose to avoid the develop-
ment of drug resistance. The present study demon-
strated that after 3 months of continuous treatment
with 1 µm Zol, osteosarcoma cell lines became less
sensitive to Zol inhibition and resistant cell lines were
then progressively established. Furthermore, this
Fig. 4 FPPS siRNA increases the Zol-induced blockade of the cell cycle in S phases in osteosarcoma cell lines. Cell
cycle distribution of osteosarcoma cell lines (FPPS siRNA versus control siRNA) treated or not treated with 10 µm Zol
for 48 hrs were analyzed by propidium iodide staining and FACS analysis.
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resistance appeared to be independent of the MDR
phenotype and was clearly related to a differential
expression of FPPS.
To exert its activities, Zol must be internalized by
cells. Although the mode of Zol internalization is still
controversial, two mechanisms have been proposed:
first, cellular uptake of Zol may require fluid-phase
endocytosis in osteoclasts [27]; in the second case,
integrins located at the cell membrane could repre-
sent a binding site for Zol which could explain why
Zol is able to inhibit cell adhesion and that RGD pep-
tide prevents the Zol effects on osteosarcoma cell
lines [13]. However, it remains unclear whether cell
types other than osteoclasts can internalize BPs [27].
Recently, Notarnicola et al. demonstrated that high
FPPS activity level correlates to a stronger inhibition
of cellular apoptosis in colorectal cancer cells [28].
Similarly, Ortiz-Gomez et al. demonstrated that over-
expression of FPPS confers resistance to rise-
dronate in Leishmania major and that the degree of
resistance was correlated with an increase in this
enzymatic activity [29]. These data strongly support
our present results and strengthen the pivotal func-
tion of FPPS in the Zol-resistance mechanism.
Although FPPS is considered as the main target of
nitrogen-containing-BPs, the inhibition of prenylation
being the most likely explanation for their biological
effects, van Beek et al. evidenced that undetermined
additional mechanisms could be involved which may
be also proposed for specific resistance mechanisms
in certain specific cell types [30].
In the present study, we wondered what could be
the origin of the Zol-induced resistance mechanism:
an innate or an acquired resistance mechanism? In
fact, the results did not allow us to distinguish
between these two hypotheses. The main argument
in favor of an innate resistance mechanism is the dif-
ferential FPPS expression of OSRGA osteosarcoma
sub-clones composing the heterogenous 'parental'
OSRGA cell line. Indeed, Zol treatment exerts a
Fig. 5 Geranylgeraniol (GGO) reverses FPPS siRNA effects in osteosarcoma cell lines. (A) Rat (OSRGA) and human
(MG63, SAOS2) osteosarcoma cell lines were transfected with FPPS siRNA and treated 24 hrs after with increasing
concentrations of Zol (0.1–100 µm) for 72 hrs in the presence or not of 25 µm GGO. The number of viable cells was
then determined using the XTT assay. Graphs represent the mean values of three independent experiments performed
in triplicate. Error bars represent the standard deviation. ***P < 0.001. Statistical evaluation of the data was performed
using the ANOVA test. (B) Western blot analysis of unprenylated RAP1A (unRAP1A) form. Cells transfected with con-
trol siRNA or with FPPS siRNA combined with 25 µm GGO were treated with 1 and 10 µm Zol for 24 and 48 hrs. All
experiments were repeated three times, and a representative blot is shown.
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selective inhibitory effect on cancer cells expressing
less FPPS and after several weeks of culture, FPPS
overexpressing cells become predominant and
emerge from the parental population (Fig. 6B) [28].
Interestingly, we observe the same kind of hetero-
geneity in patients. We haven't yet correlated this
with sensitivity to Zol treatment but it will be per-
formed in a clinical trial and we could expect using
FPPs expression level as a prognosis factor of Zol
efficacy. On the other hand, the effect of Zol treat-
ment on FPPS expression is in favor of an acquired
resistance mechanism. Indeed, 72 hrs treatment 
with low doses of Zol (1–104 pM) increased FPPS
expression in OSRGA cells (Fig. 6A) inducing the
development of FPPS overexpressing tumor cells
(Fig. 1D). Similar involvement has been envisaged in
myeloma cells [31]. This hypothesis was also
strengthened by Ortiz-Gomez et al. who obtained
resistant cell lines by stepwise selection in the pres-
ence of risedronate, resulting in the development of
resistant promastigotes exhibiting increased levels of
FPPS at the transcriptional and the translational lev-
els [29]. These authors considered that as a result of
drug pressure, cells overcame the effects of rise-
dronate by overexpressing the target protein. Such
modification has been already observed in osteosar-
coma patients treated with chemotherapy. Indeed,
after comparison of primary biopsy tissue with that
removed after metastasectomy, genetic changes
acquired by the tumors have been demonstrated [32, 33].
level was determined by semi-quantitative RT PCR under the same conditions of Zol treatment. The 18S was used as
a control. (B) Similar experiments were performed with higher concentrations of Zol (0.1–100 µM) in two OSRGA
clones obtained by limiting dilution. ***P < 0.001. Statistical evaluation of the data was performed using the ANOVA test.
(C) Transcriptional analysis of FPPS in seven human osteosarcoma samples analyzed by semi-quantitative RT-PCR.
Fig. 6 Dual origin of Zol-resistance: innate and/or
acquired. (A) OSRGA osteosarcoma cell lines were
treated with increasing low concentration of Zol (1–104 pM)
for 72 hrs. The number of viable cells was then deter-
mined using a XTT assay. Graphs represent the average
values of three independent experiments performed in
triplicate. Error bars represent the standard deviation.
Farnesyl diphosphate synthase (FPPS) transcription
J. Cell. Mol. Med. Vol 12, No 3, 2008
939© 2008 The Authors
Journal compilation © 2008 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
An acquired resistance to BPs was also reported by
Papapoulos et al. in Paget's disease [34]. These
authors argued that resistance to the action of BPs in
Paget's disease is caused by disease-related factors
rather than decreased responsiveness of the molec-
ular target in contrast to the present data. They sup-
ported this hypothesis with studies using statins that
target the same intracellular biochemical pathway
upstream of FPPS, these studies showed no evi-
dence of development of resistance to their action
[35, 36]. They also presented data suggesting that
acquired resistance is specific for pamidronate and
does not extend to other nitrogen-containing BPs. In
summary, various and concomitant resistance mech-
anisms cannot be excluded: direct or indirect effects
on FPPS, innate and/or acquired mechanisms.
Chemotherapy resistance in osteosarcoma is well
documented [37]. Osteosarcoma cells are subjected
to genetic disturbances such as alterations in the
tumor suppressor pathways centered on p53 and Rb
[38, 39], changes in oncogenes/anti-oncogenes such
as deletions in p16INK4A (cyclin-dependent kinase
inhibitor 2A), c-fos overexpression and amplification
of cyclin-dependent kinase 4 [40–42]. These genet-
ics instabilities lead to heterogenic cell populations
within the same tumor and to the emergence of
resistant tumor cells. The most described resistance
phenomena concern widely used chemotherapeutic
agents such as cisplatin, doxorubicin or methotrex-
ate. In these cases, the resistance mechanisms
involved are mutation of the drug target, up- or down-
regulation of the drug target, decreased drug uptake,
drug inactivation, increased drug elimination and
increased DNA repair [43–45]. Multidrug resistance
phenotype (MDR), due to P-gp or related protein
overexpression is the most reported resistance
mechanism. In osteosarcoma, MDR1 [46] or P-gp
[47] expression could be used as a prognostic mark-
er for sensitivity to chemotherapy, allowing the selec-
tion of patients for whom alternative treatments may
be considered. Recently, other prognostic factors
have been described, such as the expression level of
clusterin/apolipoprotein J [48] or expression of a preg-
nane xenobiotic receptor (PXR), a major inducer of
cytochrome P450 3A4 [49]. Therefore, these factors
may also represent predictive markers correlating
with the response of cancer cells to chemotherapy.
We described in ostesarcoma a Zol-resistance
mechanism specific to nitrogen-containing BPs
which did not confer simultaneous resistance to other
unrelated drugs. In this context, drug resistance
could be circumvented using multiple drugs with
different cellular targets and different mechanisms of
action. For instance, when Zol is associated with
ifosfamide in rat osteosarcoma, enhanced tumor
regression and tissue repair have been observed
[11]. In the future, Zol could be combined with other
chemotherapeutic agent to increase therapeutic
efficacy and avoid the emergence of resistance
mechanism [50].
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